Document text
Principal Investigator: William Paul Duprex
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $587,096
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
The outbreak of COVID-19 has severely impacted global health and the economy. Cost-effective, highly
efficacious therapeutics are urgently needed. Camelid VHH antibodies or nanobodies (Nbs) are small, highly
stable, easily bioengineered, and can be rapidly and economically manufactured from microbes. They are
highly robust and are flexible for administration, including possible delivery by nebulization. Together these
unique properties of Nbs make their uses against respiratory viruses such as SARS-CoV-2 especially
appealing.
We recently developed a disruptive proteomic technology for large-scale identification of multi-epitope, drug-
quality Nbs (Xiang et. al, Cell Systems. 2021). Using this technology, we identified > 8,000 high-affinity Nbs for
the SARS-CoV-2 spike (S) receptor-binding domain (RBD) including Nbs that target highly neutralizing
epitopes with sub-pM affinities and can neutralize SARS-CoV-2 at sub-ng/ml concentrations, which are
unprecedented for antiviral antibody fragments. Structural proteomics revealed multiple distinct epitopes and
potential neutralization mechanisms. Bioengineering of multi-epitope and multivalent constructs improved the
potency to below 0.1 ng/ml (Xiang, et. al, Science. 2020). Most recently, we have demonstrated the high
preclinical efficacy of an ultrapotent and stable trimeric Nb construct (PiN-21) for inhalation treatment of SARS-
CoV-2 infection in a sensitive COVID-19 model (Nambulli, et. al, Science Advances. 2021). Intranasal delivery
of PiN-21 at 0.6 mg/kg substantially reduces viral burdens in both airways. Critically, aerosol delivery of PiN-21
at 0.2 mg/kg decreases lung viral titers by 6-logs, minimizing lung pathology post-infection and preventing viral
pneumonia. Combined with the marked stability and low production cost, this innovative therapy may provide a
convenient and cost-effective option to mitigate the evolving pandemic and future events.
In the revision, we aim to identify and characterize highly potent Nbs that are highly resistant to the variants of
concern (VOCs) of SARS-CoV-2, investigate the neutralization mechanisms by structural approaches, and
develop ultrapotent Nb constructs into safe and effective therapeutics. Our central hypothesis is that Nbs can
be bioengineered into multivalent and ultrapotent forms to resist the mutational escape and the variants of
concerns (VOCs) of SARS-CoV-2.
Completion of our proposed studies will lead to cost-effective and convenient COVID-19 therapeutic
candidates for translation into clinical trials. High-resolution structural studies will provide critical insights into
how Nbs uniquely target the virus for high-affinity binding and neutralization. Critically, this project will serve as
the testbed of our multidisciplinary platform to develop potent therapeutic and diagnostic reagents for future
pandemics caused by coronaviruses or other pathogens.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Aerosols><Affinity><Antibodies><Antibody Fragments><Antigenic Determinants><Binding><Binding Determinants><Bioavailability><Biological Availability><Biomedical Engineering><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 outbreak><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 outbreak><COVID19 virus><CV-19><Cell Body><Cells><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Communities><Computer software><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Cricetinae><Deposit><Deposition><Development><Diagnostic Reagent><Dose><Drug Storage><Drugs><Epitope Mapping><Epitopes><Event><Future><Genetic Alteration><Genetic Change><Genetic defect><Genotype><Goals><Hamsters><Hamsters Mammals><Human><IgG><Immunoglobulin Fragments><Immunoglobulin G><Infection><Inhalation><Inhaling><Innovative Therapy><Lung><Lung Respiratory System><Medication><Microbe><Modeling><Modern Man><Molecular Interaction><Mutation><Nebulizer><Pharmaceutical Preparations><Physiologic Availability><Primates><Primates Mammals><Production><Property><Proteomics><Pulmonary Body System><Pulmonary Organ System><Pulmonary Pathology><Reporting><Research><Resistance><Resolution><Respiratory System><Respiratory Tracts><Respiratory tract structure><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Software><Structure><System><Technology><Therapeutic><Therapeutic Agents><Translations><Viral><Viral Antibodies><Viral Burden><Viral Load><Viral Load result><Viral Pneumonia><Virus><Wuhan coronavirus><aerosolized><anti-viral antibody><bio-engineered><bio-engineers><bioengineering><biological engineering><clinical applicability><clinical application><corona virus><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 outbreak><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><cost effective><design><designing><determine efficacy><developmental><drug development><drug quality><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><emerging pathogen><evaluate efficacy><examine efficacy><flexibility><flexible><future pandemic><genome mutation><global health><hCoV19><improved><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><interdisciplinary approach><interest><lung pathology><manufacture><multidisciplinary><multidisciplinary approach><nCoV2><nanobodies><nanobody><nebulization><nebulize><new drug treatments><new drugs><new pathogen><new pharmacological therapeutic><new therapeutics><new therapy><new vaccines><next generation therapeutics><next generation vaccines><next pandemic><novel><novel drug treatments><novel drugs><novel pathogen><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><novel vaccines><outbreak of SARS-CoV-2><pandemic><pandemic disease><pathogen><pre-clinical efficacy><pre-clinical evaluation><preclinical efficacy><preclinical evaluation><prevent><preventing><protein folding><pulmonary><rational design><receptor binding><receptor bound><resistant><resolutions><respiratory virus><sdAb><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><single domain antibodies><spike proteins on SARS-CoV-2><structural biology><therapeutic candidate><therapeutically effective><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><translation><translational opportunities><translational potential><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><variants of concern>